|
|
|
|
|
Highlights from the 2023 ASCO Genitourinary Cancers Symposium
|
|
|
|
|
|
Oral Abstracts: Prostate Cancer
|
|
| TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
|
| Neeraj Agarwal, MD, FASCO
|
| Neeraj Agarwal presented the TALAPRO-2 phase III study evaluating the combination of the poly(ADP-ribose) polymerase inhibitor talazoparib and enzalutamide versus enzalutamide and placebo as first-line treatment in patients with metastatic castration resistant prostate cancer.
|
|
|
|
|
|
| Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy |
| Alan Bryce, MD
|
| Alan Bryce presented on behalf of the study team interim overall survival data of TRITON3, A Phase 3 Study of Rucaparib vs Physician’s Choice of Therapy in Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Deficiency.
|
|
|
|
|
|
| PARP Inhibitors in Metastatic Castration Resistant Prostate Cancer (mCRPC): TRITON3 and TALAPRO-2
|
| Elena Castro, MD, Ph.D.
|
| Elena Castro provided a discussion of PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) immediately following the presentation of updated data from TRITON3 and TALAPRO-2.
|
|
|
|
|
|
|
Advanced Prostate Cancer: New Targets, New Drugs, New Victories?
|
|
| The Androgen Receptor Remains the Main Driver of Disease: Towards Third-Generation Inhibitors?
|
| Alice Bernard-Tessier, MD
|
| The 2023 GU ASCO annual meeting included a session on advanced prostate cancer, specifically new targets, new drugs, and new victories, featuring a presentation by Dr. Alice Bernard-Tessier discussing the potential of third generation inhibitors of the androgen receptor.
|
|
|
|
|
|
| Final Overall Survival in PROpel: Abiraterone and Olaparib Versus Abiraterone and Placebo as First-Line Therapy for mCRPC
|
| Noel W. Clarke, MBBS, FRCS, ChM |
| Noel Clarke discussed the final overall survival results in PROpel, a phase 3 trial assessing abiraterone and olaparib versus abiraterone and placebo as first-line therapy for mCRPC. |
|
|
|
|
|
|
|
|
|
|
| Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study
|
| Maha Hussain, MD, FACP, FASCO
|
| Maha Hussain discussed efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the phase 3 ARASENS study.
|
|
|
|
|
|
|
Trials in Progress: Prostate Cancer
|
|
| Darolutamide plus ADT Versus ADT in Metastatic Hormone-Sensitive Prostate Cancer: Open-Label Single-Arm Study with an External Control Arm (ARASEC)
|
| Neal D. Shore, MD, FACS
|
| Neal Shore discussed the trial design of ARASEC, an open-label single-arm study with an external control of darolutamide plus ADT versus ADT in metastatic hormone-sensitive prostate cancer.
|
|
|
|
|
|
| A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX
|
| Daniel Spratt, MD
|
| Daniel Spratt presented the study design for OPTYX, a multi-center, prospective observational study of patients with prostate cancer being treated with relugolix.
|
|
|
|
|
|
| EVOLUTION: Phase II Study of Radionuclide 177Lu-PSMA-617 Therapy Versus 177Lu-PSMA-617 in Combination with Ipilimumab and Nivolumab for Men with mCRPC (ANZUP 2001)
|
| Shahneen Sandhu, MBBS, FRACP
|
| Shahneen Sandhu presented the study design for the EVOLUTION trial, a phase II study of 177Lu-PSMA-617 in combination with ipilimumab and nivolumab versus 177Lu-PSMA-617 alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
|
|
|
|
|
|
| A Phase II Trial Modifying Metabolic Syndrome and Cardiovascular Risk for Patients with Prostate Cancer on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (ProTrio)
|
| Andrew Warren Hahn, MD
|
| Andrew Hahn presented the study design for the ProTrio trial, a phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on androgen deprivation therapy using a risk factor modification program and continuous Fitbit® monitoring.
|
|
|
|
|
|
|
|
|
|
|
| LuCAB: A Phase I/II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with mCRPC |
| Arun Azad, MBBS, Ph.D., FRACP |
| Arun Azad discussed the trial design of LuCAB, a phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA-617 was recently FDA-approved for use in the post-taxane, post-antiandrogen setting in patients with mCRPC.
|
|
|
|
|
|
|
Poster Session: Prostate Cancer
|
|
| Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer
|
| Geoffrey T. Gotto, MD, MPH
|
| Geoffrey Gotto presented administrative data from Alberta, Canada examining the practice patterns of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
|
|
|
|
|
|
| Association of Intermittent vs Continuous Androgen Deprivation Therapy with Cardiovascular Disease and Endocrine/metabolic Disorders in Patients with Metastatic Prostate Cancer
|
| Alicia K. Morgans, MD, MPH
|
| Alicia Morgans presented on the association between intermittent as compared to continuous androgen deprivation therapy (ADT) and cardiovascular disease and endocrine/metabolic disorders in patients with metastatic prostate cancer.
|
|
|
|
|
|
| Influence of Molecular Imaging on Patient Selection for Treatment Intensification Prior to Salvage Radiation Therapy for Prostate Cancer: A Post Hoc Analysis of the PROPS Trial
|
| Samuel Tremblay, MD
|
| Samuel Trembley presented a post hoc analysis of the PROPS trial assessing the influence of molecular imaging on patient selection for treatment intensification in the context of salvage radiotherapy for prostate cancer.
|
|
|
|
|
|
| A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer (nmHSPC) with “BCRAness” Genotype (ROAR)
|
| Kamal Kant Sahu, MBBS
|
| Kamal Kant Sahu presented in Poster Session results of a phase II study assessing rucaparib monotherapy in patients with nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with a “BCRAness” genotype.
|
|
|
|
|
|
| Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual Patient Data Meta-Analysis from the MARCAP Consortium
|
| Wee Loon Ong, MBBS
|
| Wee Loon Ong presented the results of an individual patient data meta-analysis from the MARCAP consortium aimed at assessing testosterone recovering following androgen suppression (androgen deprivation therapy; ADT) and prostate radiotherapy.
|
|
|
|
|
|
|
